新型广谱氟喹诺酮类抗菌药物--德拉沙星

A novel broad-spectrum fluoroquinolones antibiotics――delafloxacin

德拉沙星(delafloxacin,商品名BAXDELA)是由日本Wakunaga制药公司和美国Melinta生物公司共同研究开发的最新一代广谱氟喹诺酮抗菌药物,于2017年6月19日被FDA批准用于治疗急性细菌性皮肤和皮肤结构感染(acute bacterial skin and skin structure infections,ABSSSI)。德拉沙星对革兰阳性菌特别是对其他喹诺酮类抗菌剂耐药的MRSA有较好疗效,光毒性低,安全性和耐受性良好。笔者就德拉沙星的基本性质、作用机制、药动学、药物相互作用、临床试验及应用等研发动态作一概述,以期能为临床用药提供帮助。

Delafloxacin（trade name BAXDELA） is the latest generation of broad-spectrum fluoroquinolone antimicrobials developed by the Japanese Wakunaga Pharmaceutical Company and Melinta Biotechnology Company in the United States. It was approved by the FDA on June 19, 2017 for the treatment of acute bacterial skin and skin structure infections（ABSSSI）. Dexafloxacin has a good effect on Gram-positive bacteria, especially MRSA resistant to other quinolones, and with low phototoxicity, good safety and tolerability. In this paper, the properties, mechanism, pharmacokinetics, drug interactions, clinical trials and applications of delafloxacin are summarized, for the purpose of providing reference for clinical treatment.